recurrent multiple myeloma Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 3 (1)

Interventional (1)

GlaxoSmithKline (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadrefractory multiple myeloma

I am/have/hadrecurrent multiple myeloma

I am/have/hadbortezomib/dexamethasone

I am/have/hadmultiple myeloma

I am/have/hadhair thinning

I am/have/hadcancer

I am/have/hadprotein concentration

I am/have/hadmeasurable disease

added new label for I am/have/had

more

I am looking for

I am looking forbortezomib

I am looking fordaratumumab

I am looking fordexamethasone

I am looking forbelantamab mafodotin

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Multi-country trial
Phase 3
For Seniors
For adults
Recruiting in 100s
Interventional Study
all
Family Medicine
Recruiting

Evaluation of Efficacy and Safety of Belantamab Mafodotin Bortezomib and Dexamethasone Versus Daratumumab Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.

refractory multiple myeloma

daratumumab

belantamab mafodotin

recurrent multiple myeloma

bortezomib/dexamethasone

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.